Vyvanse for attention deficit hyperactivity disorder (ADHD) Vyvanse is FDA-approved to treat ADHD in adults and in children ages 6 years and older
10.3389/fendo.2021.700705 43 MeraP.LaueK.FerronM.ConfavreuxC.WeiJ.MassG.et al (2016)
Indication Segment Insights and Analysis: Based on the indication, the GLP-1 Receptor Agonist market is segmented into type 2 diabetes, obesity, cardiovascular diseases, liver cirrhosis, Non-alcoholic fatty liver disease (NAFLD), and others
While rare, hypersensitivity reactions can occur with any medication
However, native GLP-1 has a limited half-life (1.55 min) due to its degradation by the enzyme Dipeptidyl peptidase 4 (DPP-4), necessitating the development of GLP-1 receptor agonists (GLP-1RAs) with longer activity (Campbell and Drucker 2013)
Studies from Novo Nordisk show an almost 25% reduction in adverse kidney outcomes for diabetes patients with CKD, and the company is trying to get Wegovys indications expanded to include CKD before years end